When does atogepant patent expiration occur?
Atogepant's primary patent is set to expire in 2037 [1].
What are the key patents protecting atogepant?
The principal patent covering atogepant is U.S. Patent No. 10,583,060 [1]. This patent is listed in the FDA's Orange Book for atogepant, marketed as Qulipta [1].
What is the expected timeline for atogepant market exclusivity?
Market exclusivity for atogepant, based on its primary patent protection, is anticipated to last until 2037 [1].
Can atogepant patents be challenged?
Like many pharmaceuticals, atogepant's patents are subject to potential challenges. Such challenges can arise from various entities, including generic drug manufacturers seeking to enter the market earlier than the patent expiration date [2]. Information on specific patent litigation or challenges related to atogepant would be available through patent tracking resources [1][2].
What is atogepant used for?
Atogepant, sold under the brand name Qulipta, is a medication used for the preventive treatment of migraine [1]. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists [3].
How does atogepant compare to other migraine preventives?
Atogepant is one of several CGRP-targeting therapies available for migraine prevention. Other treatments in this class include erenumab, fremanezumab, and galcanezumab, which are injectable monoclonal antibodies, and rimegepant, which is an oral CGRP receptor antagonist approved for both acute treatment and prevention of migraine [3]. Atogepant's oral formulation and specific mechanism of action differentiate it within this therapeutic area [3].
Who developed and markets atogepant?
AbbVie Inc. is the company that developed and markets atogepant (Qulipta) [1].
What are the potential risks or side effects associated with atogepant?
While specific patient concerns can vary, common side effects reported for atogepant may include upper respiratory tract infection, nausea, and fatigue [4]. Detailed patient information and potential risks are typically outlined in prescribing information and discussed with healthcare providers.
Sources:
1. DrugPatentWatch.com, Atogepant Patent Expiration [1]
2. DrugPatentWatch.com [2]
3. FDA Approved Drugs [3]
4. Qulipta Prescribing Information [4]